Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 16;5(7):e27484.
doi: 10.2196/27484.

Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid

Affiliations

Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid

Danielle Shojaie et al. JMIR Form Res. .

Abstract

Background: In cancers with a chronic phase, patients and family caregivers face difficult decisions such as whether to start a novel therapy, whether to enroll in a clinical trial, and when to stop treatment. These decisions are complex, require an understanding of uncertainty, and necessitate the consideration of patients' informed preferences. For some cancers, such as medullary thyroid carcinoma, these decisions may also involve significant out-of-pocket costs and effects on family members. Providers have expressed a need for web-based interventions that can be delivered between consultations to provide education and prepare patients and families to discuss these decisions. To ensure that these tools are effective, usable, and understandable, studies are needed to identify patients', families', and providers' decision-making needs and optimal design strategies for a web-based patient decision aid.

Objective: Following the international guidelines for the development of a web-based patient decision aid, the objectives of this study are to engage potential users to guide development; review the existing literature and available tools; assess users' decision-making experiences, needs, and design recommendations; and identify shared decision-making approaches to address each need.

Methods: This study used the decisional needs assessment approach, which included creating a stakeholder advisory panel, mapping decision pathways, conducting an environmental scan of existing materials, and administering a decisional needs assessment questionnaire. Thematic analyses identified current decision-making pathways, unmet decision-making needs, and decision support strategies for meeting each need.

Results: The stakeholders reported wide heterogeneity in decision timing and pathways. Relevant existing materials included 2 systematic reviews, 9 additional papers, and multiple educational websites, but none of these met the criteria for a patient decision aid. Patients and family members (n=54) emphasized the need for plain language (46/54, 85%), shared decision making (45/54, 83%), and help with family discussions (39/54, 72%). Additional needs included information about uncertainty, lived experience, and costs. Providers (n=10) reported needing interventions that address misinformation (9/10, 90%), foster realistic expectations (9/10, 90%), and address mistrust in clinical trials (5/10, 50%). Additional needs included provider tools that support shared decision making. Both groups recommended designing a web-based patient decision aid that can be tailored to (64/64, 100%) and delivered on a hospital website (53/64, 83%), focuses on quality of life (45/64, 70%), and provides step-by-step guidance (43/64, 67%). The study team identified best practices to meet each need, which are presented in the proposed decision support design guide.

Conclusions: Patients, families, and providers report multifaceted decision support needs during the chronic phase of cancer. Web-based patient decision aids that provide tailored support over time and explicitly address uncertainty, quality of life, realistic expectations, and effects on families are needed.

Keywords: clinical trial; decision support techniques; medullary thyroid cancer; mobile phone; oncology; patient decision aids; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: JAS is a member of the Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry and is supported by GlaxoSmithKline, Novo Nordisk, Astra Zeneca, and Eli Lilly. She receives institutional research funding from Exelixis and Eli Lilly. MEC is part of the advisory board in Exelixis. All other authors declare that they do not have any real or perceived conflicts of interest.

Figures

Figure 1
Figure 1
The Ottawa Decision Support Framework. *Inadequate support and resources to make/implement the decision include: information inadequacy/overload; inadequate perceptions of others' views/practices; social pressure; difficult decisional roles; inadequate experience; self-efficacy, motivation, skills; inadequate emotional support, advice, instrumental help; and inadequate financial assistance, health/social services. Copyright 2019, Ottawa Hospital Research Institute [16,20].
Figure 2
Figure 2
The International Patient Decision Aid Standards Collaboration model for the systematic development of a patient decision aid [18].
Figure 3
Figure 3
Decision support design guide. Left column: top-rated decision support needs from our assessment. Right column: proposed decision support strategies for addressing each need.

Similar articles

Cited by

References

    1. Eddy DM. Clinical decision making: from theory to practice. Rationing by patient choice. J Am Med Assoc. 1991 Jan 02;265(1):105–8. doi: 10.1001/jama.265.1.105. - DOI - PubMed
    1. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006 Nov 01;107(9):2134–42. doi: 10.1002/cncr.22244. doi: 10.1002/cncr.22244. - DOI - DOI - PubMed
    1. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567–610. doi: 10.1089/thy.2014.0335. http://europepmc.org/abstract/MED/25810047 - DOI - PMC - PubMed
    1. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134–41. doi: 10.1200/JCO.2011.35.5040. http://europepmc.org/abstract/MED/22025146 - DOI - PMC - PubMed
    1. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639–46. doi: 10.1200/JCO.2012.48.4659. http://europepmc.org/abstract/MED/24002501 - DOI - PMC - PubMed